Koji Sakamoto

Assistant Professor

Nagoya University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Koji Sakamoto is an Assistant Professor at Nagoya University in Japan. His research focuses on interstitial lung disease, including its complications related to autoimmune responses and the impact of pulmonary rehabilitation. Recent publications highlight his work on predicting mortality in interstitial lung disease and evaluating treatment practices during the COVID-19 pandemic.

Articles (18)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

Shintaro Iwama

Nagoya University

JAPAN

View details

Taiki Furukawa

Nagoya University Hospital

JAPAN

View details

shinichi arizono

Professor

Seikei University

JAPAN

View details

Makoto Ishii

Professor

Nagoya University

JAPAN

View details

Ryo Kozu

Nagasaki University Graduate School of Biomedical Sciences

JAPAN

View details

Akira Ando

Assistant Professor

Nagoya University Hospital

JAPAN

View details

Naozumi Hashimoto

Nagoya University Graduate School of Medicine

JAPAN

View details

Tomoko Kobayashi

Nagoya University Hospital

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Koji Sakamoto

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report

Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report

Mild elevation of pulmonary vascular resistance predicts mortality regardless of mean pulmonary artery pressure in mild interstitial lung disease

Inhalation adherence for asthma and COPD improved during the COVID-19 pandemic: a questionnaire survey at a university hospital in Japan.

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial

Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?

Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy

Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy

mtDNA in bronchoalveolar lavage fluid is a prognostic factor for IPF and AE-IPF

BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts

Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis

Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis

Size and surface modification of silica nanoparticles affect the severity of lung toxicity by modulating endosomal ROS generation in macrophages

Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease

The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease

Clinical burden of immune checkpoint inhibitor-induced pneumonitis

Reply to “Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors”

Collaborators (8)

Shintaro Iwama

Taiki Furukawa

shinichi arizono

Makoto Ishii

Ryo Kozu

Akira Ando

Naozumi Hashimoto

Tomoko Kobayashi

Make your next move.